MoonLake Immunotherapeutics 8K

MoonLake Immunotherapeutics reported positive Phase 3 IZAR-1 topline efficacy and safety results for sonelokimab in psoriatic arthritis and released Q2 2026 financials showing strong liquidity and funding runway with key upcoming regulatory and clinical milestones.

On August 10, 2026, MoonLake Immunotherapeutics announced positive topline Week 16 Phase 3 IZAR-1 trial results for 60 mg sonelokimab in biologic‑naïve adults with active psoriatic arthritis, showing the primary endpoint ACR50 response rate of 42.1% and strong secondary endpoint responses (including ACR20 of 66.5%, MDA of 41.2%, and PASI90 of 61%) with a blinded safety profile consistent with prior studies and no new safety signals, while also reporting second quarter 2026 financial results indicating $537.0 million in cash, cash equivalents and short‑term marketable debt securities, an expected cash runway to mid‑2028, access to up to $400 million in additional non‑dilutive funding from a Hercules Capital debt facility, and decreased R&D and G&A expenses versus the prior quarter, alongside a timeline of key upcoming regulatory and clinical milestones across HS, PPP, PsA, and axSpA programs.

Filing Facts

CIK

1821586

Ticker

MLTX

Form

8K

Source Type

fda

Accession

0001213900-26-086939

Alert Tier

7